|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
100,490,000 |
Market
Cap: |
2.66(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$19.98 - $78.03 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : 5.1 |
Insider 6 Months : 5.1 |
Insider 3/6 Months : 10.6 |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapies for metabolic and endocrine disorders. Co.'s primary clinical program's drug candidate, VK2809, is an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRss). Co. is also developing VK0214, which is also an orally available, tissue and receptor-subtype selective agonist of TRss for X-linked adrenoleukodystrophy, a rare X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
1,240 |
1,240 |
1,240 |
1,240 |
Total Buy Value |
$29,943 |
$29,943 |
$29,943 |
$29,943 |
Total People Bought |
1 |
1 |
1 |
1 |
Total Buy Transactions |
1 |
1 |
1 |
1 |
Total Shares Sold |
0 |
299,014 |
992,508 |
1,844,768 |
Total Sell Value |
$0 |
$12,781,795 |
$59,902,240 |
$100,201,256 |
Total People Sold |
0 |
3 |
6 |
6 |
Total Sell Transactions |
0 |
3 |
17 |
26 |
End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Foehr Matthew W |
|
|
2025-04-11 |
4 |
OE |
$8.00 |
$166,288 |
D/D |
20,786 |
132,036 |
|
- |
|
Rouan Sarah Kathryn |
|
|
2025-03-31 |
4 |
B |
$24.15 |
$29,943 |
D/D |
1,240 |
1,240 |
0.01 |
10% |
|
Zante Greg |
Chief Financial Officer |
|
2025-01-06 |
4 |
S |
$42.69 |
$2,150,595 |
D/D |
(50,309) |
165,259 |
|
33% |
|
Lian Brian |
President & CEO |
|
2025-01-06 |
4 |
S |
$42.68 |
$8,313,601 |
D/D |
(194,490) |
2,366,570 |
|
33% |
|
Mancini Marianna |
Chief Operating Officer |
|
2025-01-06 |
4 |
S |
$42.69 |
$2,317,599 |
D/D |
(54,215) |
374,134 |
|
33% |
|
Zante Greg |
Chief Financial Officer |
|
2025-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
66,200 |
215,568 |
|
- |
|
Lian Brian |
President & CEO |
|
2025-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
256,133 |
2,561,060 |
|
- |
|
Mancini Marianna |
Chief Operating Officer |
|
2025-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
66,200 |
428,349 |
|
- |
|
Macartney Lawson |
|
|
2024-11-08 |
4 |
S |
$68.67 |
$137,333 |
D/D |
(2,000) |
47,965 |
|
57% |
|
Macartney Lawson |
|
|
2024-11-08 |
4 |
OE |
$5.80 |
$11,600 |
D/D |
2,000 |
49,965 |
|
- |
|
Zante Greg |
Chief Financial Officer |
|
2024-10-28 |
4 |
AS |
$74.56 |
$10,089,164 |
D/D |
(131,687) |
149,366 |
|
-64% |
|
Zante Greg |
Chief Financial Officer |
|
2024-10-28 |
4 |
OE |
$4.68 |
$704,282 |
D/D |
94,001 |
281,053 |
|
- |
|
Rouan Sarah Kathryn |
|
|
2024-10-25 |
4 |
AS |
$80.89 |
$889,790 |
D/D |
(11,000) |
0 |
|
-64% |
|
Rouan Sarah Kathryn |
|
|
2024-10-25 |
4 |
OE |
$4.88 |
$53,680 |
D/D |
11,000 |
11,000 |
|
- |
|
Singleton J Matthew |
|
|
2024-10-25 |
4 |
AS |
$79.50 |
$1,272,000 |
D/D |
(16,000) |
9,500 |
|
-64% |
|
Singleton J Matthew |
|
|
2024-10-25 |
4 |
OE |
$4.48 |
$71,680 |
D/D |
16,000 |
25,500 |
|
- |
|
Singleton J Matthew |
|
|
2024-09-20 |
4 |
AS |
$69.50 |
$715,850 |
D/D |
(10,300) |
9,500 |
|
-54% |
|
Singleton J Matthew |
|
|
2024-09-20 |
4 |
OE |
$1.19 |
$12,257 |
D/D |
10,300 |
19,800 |
|
- |
|
Lian Brian |
President & CEO |
|
2024-09-20 |
4 |
AS |
$70.43 |
$15,308,553 |
D/D |
(216,130) |
2,304,927 |
|
-54% |
|
Lian Brian |
President & CEO |
|
2024-09-20 |
4 |
OE |
$7.77 |
$1,290,830 |
D/D |
166,130 |
2,521,057 |
|
- |
|
Lian Brian |
President & CEO |
|
2024-08-21 |
4 |
AS |
$69.90 |
$69,900 |
D/D |
(1,000) |
2,354,927 |
|
-39% |
|
Lian Brian |
President & CEO |
|
2024-08-21 |
4 |
OE |
$7.77 |
$7,770 |
D/D |
1,000 |
2,355,927 |
|
- |
|
Singleton J Matthew |
|
|
2024-08-21 |
4 |
AS |
$69.72 |
$397,430 |
D/D |
(5,700) |
9,500 |
|
-39% |
|
Singleton J Matthew |
|
|
2024-08-21 |
4 |
OE |
$1.19 |
$6,783 |
D/D |
5,700 |
15,200 |
|
- |
|
Singleton J Matthew |
|
|
2024-08-19 |
4 |
AS |
$60.01 |
$995,453 |
D/D |
(16,000) |
9,500 |
|
-36% |
|
183 Records found
|
|
Page 1 of 8 |
|
|